NewsBenzingaFulgent Genetics eleva la guía de BPA ajustado para el año fiscal 2026 de $(2.35)-$(2.22) a $(1.75)-$(1.65) frente a $(2.27) estimado; reafirma la guía de ventas para el año fiscal 2026 de $330.000M-$340.000M frente a $331.700M estimado Fulgent Genetics eleva la guía de BPA ajustado para el año fiscal 2026 de $(2.35)-$(2.22) a $(1.75)-$(1.65) frente a $(2.27) estimado; reafirma la guía de ventas para el año fiscal 2026 de $330.000M-$340.000M frente a $331.700M estimado Benzinga 2026.11.05 21:17 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82 JP Morgan Maintains Neutral on ArcBest, Raises Price Target to $164 JP Morgan Maintains Overweight on Dave, Lowers Price Target to $435 Chip Stocks Just Had Their Worst Day Since 2020: 28 of 30 Biggest Names Are in a Bear Market $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today JP Morgan Maintains Underweight on Avis Budget Gr, Lowers Price Target to $85
